SEngine Precision Medicine has engineered an innovative approach to identify and develop the next generation of cancer targeted drugs. Built on its Founders’ work of more than 25 years at the Fred Hutchinson Cancer Research Center, SEngine employs functional genomics and robotic testing of drugs in live patient organoids to match newly developed drugs to individual cancer patients. SEngine strives to fulfill the promise of personalized medicine providing cancer patients with effective, targeted, and less-toxic treatments.